FRCS Urol Practice Questions - Intercollegiate Specialty Fellowship Examination In Urology (FRCS Urol) Exam

Access More Questions

A 58-year-old man with newly diagnosed metastatic, hormone-sensitive prostate cancer (high-volume, CHAARTED criteria) is starting androgen deprivation therapy. Based on current UK practice and STAMPEDE evidence, which addition to ADT offers the greatest overall survival benefit in this setting?

Bicalutamide monotherapy External beam radiotherapy to the prostate Docetaxel chemotherapy or an androgen-receptor pathway inhibitor Immediate radical prostatectomy

Correct Answer:

Docetaxel chemotherapy or an androgen-receptor pathway inhibitor

Access more questions from this quiz

Continue to FRCS Urol Practice Questions - Intercollegiate Specialty Fellowship Examination in Urology (FRCS Urol) Exam for more practice questions and the full quiz experience.

Access More Questions